Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study

Background: The SIPPET randomized clinical trial showed that in previously untreated patients (PUPs) with severe hemophilia A, treatment with plasma-derived factor (F)VIII (pdFVIII) within the first 50 exposure days (EDs) was associated with a lower cumulative incidence of inhibitors than with recom...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Syna Miri, Frits R. Rosendaal, Kaan Kavakli, Peyman Eshghi, Soha Mohammadi Moghaddam, Sara Scardo, Behnaz Habibpanah, Mohsen Elalfy, Susan Halimeh, Gabriella Nicolò, Dilek Gökçebay, Namık Özbek, Tiraje Celkan, Ahmad Mohammadi, Mehran Karimi, Amin Shahsavani, Bariş Yılmaz, Canan Albayrak, Burcak Gunes, Zühre Kaya, Yilmaz Ay, Sinan Akbayram, Nazan Sarper, Pier Mannuccio Mannucci, Flora Peyvandi
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2024-11-01
سلاسل:	Research and Practice in Thrombosis and Haemostasis
الموضوعات:	factor VIII factor VIII/adverse events factor VIII/immunology factor VIII/therapeutic use hemophilia A/drug therapy
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2475037924002905
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!